tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Jun 2;jiad194.
doi: 10.1093/infdis/jiad194. Online ahead of print. National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative
Eileen Lee[SUP] 1 [/SUP], Benjamin Bates[SUP] 2 3 [/SUP], Nathaniel Kuhrt[SUP] 4 [/SUP], Kathleen M Andersen[SUP] 5 6 [/SUP], Aayush Visaria[SUP] 2 [/SUP], Rachel Patel[SUP] 1 [/SUP], Soko Setoguchi[SUP] 2 3 [/SUP]; N3C Consortium
Collaborators, Affiliations
Background: Anticoagulation (AC) utilization patterns and their predictors among hospitalized coronavirus disease 2019 (COVID-19) patients have not been well-described.
Methods: Using the National COVID Cohort Collaborative, we conducted a retrospective cohort study (2020-2022) to assess AC use patterns and identify factors associated with therapeutic AC employing modified Poisson regression.
Results: Among 162,842 hospitalized COVID-19 patients, 64% received AC and 24% received therapeutic AC. Therapeutic AC use declined from 32% in 2020 to 12% in 2022, especially after December 2021. Therapeutic AC predictors included age (relative risk (RR), 1.02 [95% confidence interval (CI), 1.02-1.02] per year), male (RR, 1.29 [1.27-1.32]), Non-Hispanic Black (RR, 1.16 [1.13-1.18]), obesity (RR, 1.48 [1.43-1.52]), increased length of stay (RR, 1.01; [1.01-1.01] per day), and invasive ventilation (RR, 1.64 [1.59-1.69]). Vaccination (RR, 0.88 [0.84-0.92]) and higher Charlson Comorbidity Index (CCI) (RR, 0.98 [0.97-0.98]) were associated with lower therapeutic AC.
Conclusions: Overall, two thirds of hospitalized COVID-19 patients received any AC and a quarter received therapeutic dosing. Therapeutic AC declined after the introduction of the Omicron variant. Predictors of therapeutic AC included demographics, obesity, LOS, invasive ventilation, CCI, and vaccination, suggesting AC decisions driven by clinical factors including COVID-19 severity, bleeding risks, and comorbidities.
Keywords: anticoagulation; covid-19; hospitalization.
. 2023 Jun 2;jiad194.
doi: 10.1093/infdis/jiad194. Online ahead of print. National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative
Eileen Lee[SUP] 1 [/SUP], Benjamin Bates[SUP] 2 3 [/SUP], Nathaniel Kuhrt[SUP] 4 [/SUP], Kathleen M Andersen[SUP] 5 6 [/SUP], Aayush Visaria[SUP] 2 [/SUP], Rachel Patel[SUP] 1 [/SUP], Soko Setoguchi[SUP] 2 3 [/SUP]; N3C Consortium
Collaborators, Affiliations
- PMID: 37265224
- DOI: 10.1093/infdis/jiad194
Background: Anticoagulation (AC) utilization patterns and their predictors among hospitalized coronavirus disease 2019 (COVID-19) patients have not been well-described.
Methods: Using the National COVID Cohort Collaborative, we conducted a retrospective cohort study (2020-2022) to assess AC use patterns and identify factors associated with therapeutic AC employing modified Poisson regression.
Results: Among 162,842 hospitalized COVID-19 patients, 64% received AC and 24% received therapeutic AC. Therapeutic AC use declined from 32% in 2020 to 12% in 2022, especially after December 2021. Therapeutic AC predictors included age (relative risk (RR), 1.02 [95% confidence interval (CI), 1.02-1.02] per year), male (RR, 1.29 [1.27-1.32]), Non-Hispanic Black (RR, 1.16 [1.13-1.18]), obesity (RR, 1.48 [1.43-1.52]), increased length of stay (RR, 1.01; [1.01-1.01] per day), and invasive ventilation (RR, 1.64 [1.59-1.69]). Vaccination (RR, 0.88 [0.84-0.92]) and higher Charlson Comorbidity Index (CCI) (RR, 0.98 [0.97-0.98]) were associated with lower therapeutic AC.
Conclusions: Overall, two thirds of hospitalized COVID-19 patients received any AC and a quarter received therapeutic dosing. Therapeutic AC declined after the introduction of the Omicron variant. Predictors of therapeutic AC included demographics, obesity, LOS, invasive ventilation, CCI, and vaccination, suggesting AC decisions driven by clinical factors including COVID-19 severity, bleeding risks, and comorbidities.
Keywords: anticoagulation; covid-19; hospitalization.